T

TMS Co Ltd
TSE:4891

Watchlist Manager
TMS Co Ltd
TSE:4891
Watchlist
Price: 212 JPY -3.2% Market Closed
Market Cap: 8.5B JPY
Have any thoughts about
TMS Co Ltd?
Write Note

TMS Co Ltd
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

TMS Co Ltd
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
T
TMS Co Ltd
TSE:4891
Depreciation & Amortization
ÂĄ7m
CAGR 3-Years
19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Depreciation & Amortization
ÂĄ846.8m
CAGR 3-Years
29%
CAGR 5-Years
32%
CAGR 10-Years
36%
PeptiDream Inc
TSE:4587
Depreciation & Amortization
ÂĄ2.3B
CAGR 3-Years
56%
CAGR 5-Years
35%
CAGR 10-Years
40%
Takara Bio Inc
TSE:4974
Depreciation & Amortization
ÂĄ4.7B
CAGR 3-Years
8%
CAGR 5-Years
8%
CAGR 10-Years
13%
Pharma Foods International Co Ltd
TSE:2929
Depreciation & Amortization
ÂĄ907m
CAGR 3-Years
71%
CAGR 5-Years
58%
CAGR 10-Years
43%
C
Cuorips Inc
TSE:4894
Depreciation & Amortization
ÂĄ70.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

TMS Co Ltd
Glance View

Market Cap
8.5B JPY
Industry
Biotechnology

TMS Co., Ltd. engages in the research and development of pharmaceutical products and medical devices. The company is headquartered in Fuchu-Shi, Tokyo-To and currently employs 8 full-time employees. The company went IPO on 2022-11-22. The firm conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.

Intrinsic Value
103.44 JPY
Overvaluation 51%
Intrinsic Value
Price
T

See Also

What is TMS Co Ltd's Depreciation & Amortization?
Depreciation & Amortization
7m JPY

Based on the financial report for Feb 29, 2024, TMS Co Ltd's Depreciation & Amortization amounts to 7m JPY.

What is TMS Co Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 3Y
19%

Over the last year, the Depreciation & Amortization growth was 5%. The average annual Depreciation & Amortization growth rates for TMS Co Ltd have been 19% over the past three years .

Back to Top